Anti-cancer cocktail therapy

Recently, cancer researchers at the Southwestern Medical Center at the University of Texas found that the combination of standard chemotherapy drugs and drugs that block the division of cancer cells can improve the survival of patients with advanced cervical cancer.

Anti-cancer cocktail therapy: The chemotherapeutic drug cisplatin combined with pemetrexed (a drug that blocks cancer cells) shows promising treatment results for advanced, persistent, or recurrent cervical cancer. David Miller said: We have found that pemetrexed combined with cisplatin is a less toxic and well-tolerated therapy and should be a new method for the treatment of cervical cancer.

In phase II clinical trials, Dr. Miller and colleagues at the National Cancer Institute in the United States found that for patients who have not received chemotherapy, there is a response rate of 31% after the cocktail combination therapy lasts for 7 months and there are 12 Month of total survival. The combination of cisplatin and paclitaxel, a chemotherapy drug, resulted in a tumor response rate of 29%, a duration of up to 6 months, and a 13-month overall survival.

However, Dr. Miller pointed out that cisplatin combined with pemetrexed showed less toxicity to patients than cisplatin-paclitaxel combined, so it is a better choice. The results of this study are published in the Journal of Clinical Oncology. The results of the study are very important, because the current treatment dilemma of metastatic or recurrent tumors makes the prognosis of patients poor, and there is no cure for radical diseases.

PATIENTS AND METHODS: Eligible patients were allowed to receive pemetrexed 500 mg/m 2 and intravenous infusion of cisplatin 50 mg/m 2 repeated every 21 days until progression of the disease or adverse events that prevented further treatment. Patients received no treatment prior to chemotherapy unless administered at the same time as primary radiation therapy. Subsequent doses are adjusted according to the observed toxicity and protocol guidelines. Adverse Events and Common Terminology Standard V3 Assessment of adverse events. The main measure of curative effect is tumor response according to evaluation criteria of curative effect of solid tumor. This study was stratified by existing radiation therapy.

In the United States in 2011, more than 12,000 women were diagnosed with cervical cancer. The latest data from the Centers for Disease Control shows that nearly 4,100 people have died of cervical cancer. However, according to a study in the 2014 JAMA Journal, this ratio may be even higher, with 18.6 cervical cancers per 100,000 women, instead of the 100,000 cervical cancers previously thought of as 100,000. The study also suggests that as women age, the risk of cervical cancer increases, and cervical cancer is more common among African-American women.

According to the statistics from the Centers for Disease Control and Prevention: In the past, cervical cancer deaths were the leading cause of cancer deaths in women in the United States, but cases and deaths have declined as more and more women receive regular Pap smears over the years. . Pap smear can detect cancer before cervical precancerous lesions, another factor in the decline is the use of human papilloma virus (HPV) vaccines, because HPV is the root cause of most cervical cancer.

CONCLUSIONS: Pemetrexed combined with cisplatin demonstrates activity in advanced, continuous treatment, or recurrent cervical cancer.